Algeta ASA to present interim clinical data at the 2006 Prostate Cancer Symposium in San Francisco

Algeta ASA is pleased to announce that an abstract relating to interim clinical data from a Phase II trial of its lead product Alpharadin (Radium-223) has been accepted for presentation at the 2006 Prostate Cancer Symposium in San Francisco, CA, February 24-26, 2006.

Algeta ASA is pleased to announce that an abstract relating to interim clinical data from a Phase II trial of its lead product Alpharadin (Radium-223) has been accepted for presentation at the 2006 Prostate Cancer Symposium in San Francisco, CA, February 24-26, 2006. A poster discussing the interim results will be presented in General Poster Session E between 11.30 and 13.00 on February 26, 2006. 

 Alpharadin is a novel bone-seeking radiopharmaceutical currently in Phase II trials as a potential new treatment for bone metastases in prostate cancer patients.

 The present trial (BC1-02) was initiated to study the therapeutic efficacy of Alpharadin in hormone-refractory prostate cancer patients with painful skeletal metastases using biomarkers and clinical endpoints as outcome measures.

Associated companies: